Document Detail


Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected].
MedLine Citation:
PMID:  20518617     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: The increase in type 2 diabetes mellitus is associated to cardiovascular morbidity and mortality. This review focuses on the benefits of the fixed-dose combination of perindopril and indapamide on cardiovascular and renal end points in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial.
AREAS COVERED IN THE REVIEW: In the last decade, clinical trials have indicated that blood pressure reduction and glucose lowering were effective in reducing morbidity and morbility. The ADVANCE trial has explored both intensive glucose lowering with gliclazide modified release (MR) and intensive blood pressure lowering using a fixed combination of perindopril/indapamide, on top of current treatments, including renin-angiotensin inhibitors.
WHAT THE READER WILL GAIN: In ADVANCE, perindopril/indapamide reduced a composite of macrovascular and microvascular events, also significantly decreasing cardiovascular mortality and death from any cause and reducing coronary and renal complications. The review discusses the relevance of results and the advantages of this therapeutic strategy in clinical practice.
TAKE HOME MESSAGE: ADVANCE provides a new, simple and pragmatic treatment algorithm that maximizes clinical benefits and is suitable for all type 2 diabetic patients: intensive blood pressure lowering based on combined perindopril/indapamide with intensive glucose lowering based on gliclazide MR.
Authors:
Lorenzo Ghiadoni
Related Documents :
11551377 - The calcium channel blocker controversy in patients with diabetic nephropathy: is there...
20057897 - Management of hypertension with fixed dose combinations of candesartan cilexetil and hy...
11322677 - Management of older patients with hypertension in primary care: improvement on the rule...
2913757 - How should we treat a hypertensive emergency?
18282047 - Pressure and size effects in endohedrally confined hydrogen clusters.
8694627 - A technique of positive-pressure single-lung ventilation via a silicone t-y stent.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  11     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-14     Completed Date:  2010-08-02     Revised Date:  2011-08-25    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1647-57     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy. l.ghiadoni@med.unipi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Blood Pressure / drug effects
Diabetes Mellitus, Type 2 / complications*,  physiopathology
Diuretics / administration & dosage*
Drug Therapy, Combination
Humans
Hypertension / drug therapy*
Indapamide / administration & dosage*,  adverse effects
Middle Aged
Perindopril / administration & dosage*,  adverse effects
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Diuretics; 26807-65-8/Indapamide; 82834-16-0/Perindopril
Comments/Corrections
Erratum In:
Expert Opin Pharmacother. 2010 Aug;11(11);1963

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Laropiprant + niacin for dyslipidemia and prevention of cardiovascular disease.
Next Document:  Very small embryonic-like stem cells for regenerative medicine: WO2010039241.